Phase II neoadjuvant vemurafenib trial in melanoma patients with untreated brain metastases with B-raf mutations

Conditions

Cancer | Melanoma, skin

What is the purpose of this trial?

Primary Objectives/Endpoints:

  • To determine the brain metastasis response rate in patients treated with vemurafenib prior to local therapy (LITT, SRS or resection).
  • To evaluate tumor BBB passage of vemurafenib in a subset of patients, as determined by levels of drug in brain metastases and levels of pERK in tumor.

Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Genentech, Inc.
Dates:
08/07/2013
Last Updated:
Study HIC#:
1208010666